Investigations into the CSF3R gene may help lead to better classification and precise treatment of AML.
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice—PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.
Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy.
A high level of resilience was associated with a better mental and physical health-related quality of life among patients with multiple myeloma.
New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.
In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.
Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients.
Strong efficacy and safety outcomes with this agent, which targets the molecular driver of an AML subset, have led to its approval in IDH1-mutated R/R disease.
In the emerging era of personalized treatment, it may be time to rethink which surrogate markers are used in AML clinical trials.
TROG 99.03 constitutes “the only high level evidence currently available to guide decision making for this group of patients,” says investigator Michael MacManus.